BPC-157: A Gastric Peptide Mostly Studied in Animals

The short version

BPC-157 stands for Body Protection Compound 157, a synthetic 15-amino-acid fragment based on a protein found in human gastric (stomach) juice. In animal studies it has repeatedly shown effects on tissue repair — helping tendons, ligaments, and the gut lining heal — largely by promoting the growth of new blood vessels. The catch is the species gap: almost everything known about BPC-157 comes from rats, dogs, and cell cultures. As of 2025, published human evidence amounts to only three small pilot reports, including a first safety study of two adults given it intravenously ^[1][2].

Because the human dataset is so thin, this page treats BPC-157 as investigational throughout. It is not an approved medicine anywhere, and it is sold only as a research chemical for laboratory use. Nothing on this page is a dose to take — where a number appears, it describes what a study measured, never a recommendation.

What it is

BPC-157 (also called PL 14736 or the pentadecapeptide BPC 157) is a synthetic 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from a partial sequence of a naturally occurring gastric protective protein. Its molecular formula is C62H98N16O22. Unlike most peptides, it is notably stable — resistant to breakdown in gastric acid and in the bloodstream compared to many other short peptides, though a 2022 pharmacokinetic study in rats and beagle dogs still found a very short circulating half-life of under 30 minutes, with the peptide broken down into small fragments that re-enter normal amino-acid metabolism ^[3].

How it works

The mechanism most consistently linked to BPC-157's repair effects in animal models is angiogenesis — the formation of new blood vessels. Laboratory work across chick membrane models, rat ischemia models, and human vascular endothelial cells shows BPC-157 up-regulates and promotes internalization of the VEGFR2 receptor, triggering downstream VEGFR2-Akt-eNOS (nitric-oxide) signaling that increases vessel density and speeds blood-flow recovery in damaged tissue ^[4]. Additional proposed pathways include FAK-paxillin signaling, which governs cell migration during wound closure, and sensitization of the growth-hormone receptor in tendon fibroblasts, thought to support tendon and ligament repair. It is also reported to modulate the nitric-oxide system and several neurotransmitter pathways, though these routes are less thoroughly characterized than the VEGFR2 story.

What the research shows

Human safety pilot (2025). The first published human data on intravenous BPC-157 come from a small pilot in two healthy adults (a 58-year-old man and a 68-year-old woman) given doses up to 20 mg. It was well tolerated, with no adverse events and no measurable change across cardiac, hepatic, renal, thyroid, or glucose biomarkers ^[1]. This is a safety signal from two people, not an efficacy trial, and it should be read as exactly that.

Narrative review of the human evidence (2025). A 2025 review of the literature found that, despite broad preclinical support, only three pilot studies had examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that BPC-157 should be treated as investigational given both the thin evidence base and its unregulated availability ^[2].

Pharmacokinetics (2022). The first formal PK/ADME characterization, in rats and beagle dogs, found linear pharmacokinetics, an elimination half-life under 30 minutes, and modest intramuscular bioavailability — roughly 14-19% in rats and 45-51% in dogs — with excretion via urine and bile ^[3].

Angiogenesis mechanism (2017). Across a chick chorioallantoic membrane model, a rat hindlimb-ischemia model, and human vascular endothelial cells, BPC-157 increased vessel density and accelerated blood-flow recovery in ischemic muscle via the VEGFR2-Akt-eNOS pathway; blocking cellular endocytosis blocked the effect, supporting the proposed mechanism ^[4].

Foundational cytoprotection finding (2004). In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated healing, with an ulcer-formation inhibition ratio of 45.7-65.6% at higher doses and accelerated rebuilding of the glandular epithelium and granulation tissue — one of the earliest studies establishing the cytoprotective story ^[5].

Reported effects, cautions & safety

What follows is anecdotal, not clinical evidence — a summary of what people in research-use and wellness communities report, compiled from peptide-user forums, wellness-clinic write-ups, and narrative reviews that quote community reports. None of it comes from controlled human trials, and none of it should be read as proof of an effect.

The most commonly described benefit is faster-feeling recovery from tendon, ligament, and joint injuries — stubborn tennis elbow, rotator-cuff strain, or an old sprain feeling more usable within the first one to three weeks, according to community accounts. Users also frequently describe reduced joint stiffness and pain, and — connecting to BPC-157's gastric origin — improved digestive symptoms such as less bloating and better tolerance of foods that previously caused problems. Some report a general sense of reduced inflammation, faster skin and wound healing, or better sleep, mood, and stress tolerance, though these overlap heavily with pain relief and are difficult to separate from placebo.

On the adverse side, the most common complaint by far is a local injection-site reaction — brief stinging, redness, or a small bump, usually described as fading within a day. Mild nausea or stomach upset is reported by a minority, more often with oral or sublingual products. Fatigue in the first week, headache, dizziness or lightheadedness after injecting, transient flushing, and — rarely — heart palpitations round out the community-reported profile.

The published safety cautions are more sobering than the anecdotal picture suggests. The human evidence is extremely thin: almost everything known comes from rodent studies, and as of 2025 reviews only a handful of small, uncontrolled human pilot reports exist, with large controlled trials still lacking. A large share of the foundational literature comes from one research group, which limits independent replication. BPC-157 is not approved as a medicine anywhere and moves through non-regulated channels, so product identity and purity are unverified outside formal studies. Its strong pro-angiogenic activity raises a theoretical concern in cancer, since tumors also depend on new blood-vessel growth — a mechanism-based caution, not a finding from human studies. Animal work also suggests a possible interaction with serotonin-affecting medicines and raises a theoretical, unresolved question about long-term effects of its growth-signaling activity. Separately, BPC-157 is prohibited at all times in competitive sport by the World Anti-Doping Agency, and it is unstudied in pregnancy, breastfeeding, and children.

Where it fits on the shelf

BPC-157 sits at the least-studied end of this shelf in human terms — the biggest gap here between animal promise and human confirmation of any of the four. Where GHK-Cu has decades of small but real human trials behind its topical use, and PT-141 has a full FDA approval and label, BPC-157's human record is currently three pilot reports. That does not make the preclinical work uninteresting — the angiogenesis mechanism is well characterized — but it does mean anyone reading BPC-157 research should hold animal findings and human findings in separate mental columns. See how it stacks up against the other three on the comparison page.